HepaRegeniX is developing targeted pharmacological treatments for acute and chronic liver diseases using a unique therapeutic approach. The company aims to improve patient outcomes by addressing the underlying mechanisms of liver dysfunction and promoting liver regeneration.
Funding
$37.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
VBFounders
Product
Problem
Acute and chronic liver diseases often result in liver dysfunction and limited regeneration, leading to poor patient outcomes. Current treatments may not effectively address the underlying mechanisms of these diseases.
Solution
HepaRegeniX is developing targeted pharmacological treatments designed to combat multiple liver diseases by addressing the underlying mechanisms of liver dysfunction and promoting liver regeneration. Their therapeutic approach aims to improve patient outcomes by stimulating the liver's natural regenerative capacity. The company focuses on developing novel therapies that can effectively treat both acute and chronic liver conditions.
Target Audience
The primary target audience includes patients suffering from acute and chronic liver diseases, as well as healthcare providers seeking innovative treatment options.
Features
- Development of targeted pharmacological treatments for liver diseases
- Focus on addressing underlying mechanisms of liver dysfunction
- Promotion of liver regeneration through unique therapeutic concepts